Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

2.

Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.

3.

For elderly, unfit patients, the all-oral AML regimen shows promise.

4.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

5.

New analysis helps discern benign from malignant thyroid growths


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot